Lanluma
PLLA body biostimulator for non-facial skin laxity improvement
About This Treatment
Lanluma (developed by Sinclair Pharma) is a PLLA-based body biostimulator specifically engineered for non-facial areas including neck, décolletage, arms, abdomen, thighs, and buttocks. Optimized concentration and particle size for body-specific skin structure. Long-term collagen stimulation restores skin firmness and texture.
Mechanism of Action
PLLA microparticles deposit in subcutaneous tissue, triggering macrophage-mediated chronic inflammatory response. This activates fibroblasts, promoting endogenous Type I and III collagen synthesis. PLLA itself resorbs within 12-18 months while induced collagen network persists long-term.
Indications
Expected Results
Fibroblast activation begins 3-4 weeks post-treatment with noticeable skin firmness improvement by 8-12 weeks. Results persist for 24-36 months. Multiple sessions (typically 2-3 treatments) yield superior outcomes.
Clinical Evidence
Risks & Side Effects
Injection site swelling and firmness may persist for days to 2 weeks. Rare palpable nodules or granuloma formation may occur. Over-correction should be avoided with gradual approach recommended.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition